Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

  • End date
    Apr 19, 2023
  • participants needed
  • sponsor
    Mitsubishi Tanabe Pharma Development America, Inc.
Updated on 22 August 2021
Clinical Trials Information Desk, to prevent miscommunication,
Primary Contact
NSHA-Queen Elizabeth II Health Sciences Centre (0.6 mi away) Contact
+62 other location
body mass index
spinal cord
cervical spinal cord injury
spinal cord disorder


The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury.

Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.

Condition Spinal Cord Injury, Myelopathy, Trauma
Treatment Placebo, MT-3921
Clinical Study IdentifierNCT04683848
SponsorMitsubishi Tanabe Pharma Development America, Inc.
Last Modified on22 August 2021


Yes No Not Sure

Inclusion Criteria

Additional screening criteria check may apply for qualification
Provide written informed consent prior to beginning any study procedures
Cervical spinal cord injury that meet all of the following criteria
Classified as AIS A, AIS B or AIS C
ISNCSCI neurological level of injury between C4 and C7 (for C4, the subject must have at least 1 point of motor activity between C5 to C7)
UEMS 28 at Screening
Body mass index (BMI) <40

Exclusion Criteria

Additional screening criteria check may apply for qualification
Any concomitant injury that interferes with the procedures and examinations required by study protocol, including performance, interpretation or validity of neurological examinations
Poly-traumatic Injury as defined by Injury Severity Score (ISS) values > 25
Penetrating spinal cord injuries
Complete transection of the spinal cord
Any other significant pre-existing medical conditions prior to spinal cord injury or current conditions that, in the judgement of the iInvestigator, may increase the risks associated with study participation
History of anaphylaxis or clinically significant allergic reactions to any medication
History or presence of malignancy within the last 3 years prior to screening
Subjects with current SARS-CoV-2 infection (COVID-19)
Subjects with hereditary fructose intolerance
Psychoactive substance use disorder
Participation in any clinical trial of a new chemical entity within 12 weeks prior to Screening
Female subjects who are pregnant or lactating
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note